ToolsCalculators
Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic RCC
Predicts survival in metastatic renal cell carcinoma using five clinical/laboratory factors.
Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic RCC
Karnofsky performance status <80%
LDH >1.5x upper limit of normal
Hemoglobin below the lower limit of normal
Corrected serum calcium >10 mg/dL
Time from diagnosis to treatment <1 year
Result0 factors
Favorable risk — median overall survival ~20 months.
- Risk group
- Favorable risk
- Median overall survival
- ~20 months
When to use
- Prognosticating previously untreated metastatic renal cell carcinoma before starting cytokine or targeted therapy.
Formula
Count of: KPS <80%, LDH >1.5x ULN, hemoglobin below normal, corrected calcium >10 mg/dL, time from diagnosis to treatment <1 year. Favorable 0, intermediate 1-2, poor ≥3.
Pearls and pitfalls
- Developed in the pre-targeted-therapy (cytokine) era; the IMDC/Heng model is preferred for patients treated with VEGF-targeted or immunotherapy agents.